Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer-Reference-Cited by-同舟云学术

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer

Published:2018-02-13 Issue:3 Volume:169 Page:523-530
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Dehdashti Farrokh^ORCID,Wu Ningying,Bose Ron,Naughton Michael J.,Ma Cynthia X.,Marquez-Nostra Bernadette V.,Diebolder Philipp,Mpoy Cedric,Rogers Buck E.,Lapi Suzanne E.,Laforest Richard,Siegel Barry A.

Funder

National Cancer Institute

U.S. Department of Energy

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4696-z/fulltext.html

Reference17 articles.

1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30

2. Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013

3. Lv Q, Meng Z, Yu Y et al (2016) Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer. Int J Mol Sci 17(12):2095

4. Niikura N, Liu J, Hayashi N et al (2012) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30(6):593–599

5. Niikura N, Tomotaki A, Miyata H et al (2016) Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol 27(3):480–487

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer;Journal of Nuclear Medicine;2024-09-05

2. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-14

3. Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [99mTc]Tc-ADAPT6;Pharmaceutics;2024-03-23

4. Advances and challenges in immunoPET methodology;Frontiers in Nuclear Medicine;2024-02-19

5. The Current and Future Roles of Precision Oncology in Advanced Breast Cancer;Journal of Nuclear Medicine;2024-02-01